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INTRODUCTION
The complement cascade is an important part of our innate immune system that comprises more than 30 soluble and membrane bound proteins that recognize, destroy and remove foreign bodies 1 . Following activation of the complement cascade the anaphylatoxins C3a, C4a and C5a are generated prior to the termination of the cascade with the formation of the lytic membrane attack complex. C5a is one of the most potent inflammatory mediators in the body, hence its production and activity is tightly regulated. One of the main regulatory mechanisms for C5a is its rapid cleavage by carboxypeptidases to C5a-des Arg 1 . C5a-des
Arg was originally reported to be 10-1000-fold less active than C5a depending on assay and cell type tested 2 , but recent evidence has shown C5a-des Arg to be equipotent to C5a in some circumstances 3, 4 .
There are two known G-protein coupled receptors (GPCR) to which C5a and C5a-des Arg bind: the C5a receptor (C5a1) and the C5a receptor like-2 receptor (C5a2) 5, 6 . C5a1 and C5a2 are known to have important functions in many inflammatory conditions 2 , in particular sepsis 7, 8 . C5a1 activation following C5a binding leads to G i protein activation, -arrestin recruitment and the activation of multiple intracellular signaling pathways including ERK, Akt, MAPK and PI3K 1, 2, 9 . C5a2 is known to be a non-signaling GPCR partly due to key amino acid changes in the DRY and NPXXY motifs where G-proteins are known to bind 10 , but has been shown to bind to -arrestins 11, 12 . This non-signaling nature of C5a2 has led to many postulations as to the role of this enigmatic receptor 13 , with the original thought that
C5a2 was a recycling decoy receptor similar to the chemokine receptor D6 11, 14 . C5a2 has since been shown to play an important role in many inflammatory conditions and also to have its own functional role [15] [16] [17] . The simplistic view of -arrestins merely regulating GPCR desensitization/internalization has been amended as they have been demonstrated to generate G protein-independent signals by acting as a multi-protein scaffold that can regulate multiple intracellular signaling pathways including ERK, JNK and p38 18 . In particular, -arrestin 2 has been implicated in a negative feedback loop that regulates the inflammatory response C5a2 can modulate ERK1/2 signaling in macrophages during sepsis. In key in vivo experiments -arrestin 2 knockout mice showed a significant decrease in their survival rate and a concomitant significant increase in the release of proinflammatory cytokines 19 .
GPCRs are now known to form oligomers, but the functional relevance and existence of these oligomers in native tissues is still under debate 20, 21 . It has been shown that C5a1 can form homomers 22 and heteromers with C5a2 and CCR5 23, 24 . Recent evidence has shown
C5a, but not C5a-des Arg can up-regulate the heteromer formation between C5a1 and C5a2, leading to an increase in the release of the anti-inflammatory cytokine IL-10 from human monocyte derived macrophages (HMDM) 25 . In the current study, we aimed to delineate and understand the signaling mechanism C5a1-C5a2 hetreomer formation uses to regulate the release of IL-10. Furthermore, an understanding of whether the heteromer formation regulates the release of the inflammatory mediators G-CSF and high mobility group box-1 protein (HMGB1) from HMDM was sought. Based on the current understanding surrounding C5a2, we hypothesized that due to the non G-protein induced signaling nature of C5a2, -arrestins would play a role in heteromer formation and signaling. The role of -arrestins was investigated using a widely used BRET based assay to look at the recruitment of -arrestin 2 by C5a1 and C5a2 26 . In this study, it is proposed that C5a1-C5a2 heteromer formation modulates ERK signaling through the increased recruitment of -arrestin 2 via C5a2.
RESULTS

-arrestins, C5a1 and C5a2 expression in HMDM
To understand which of the two -arrestin isoforms (1 and 2) associated with GPCRs had the highest expression in HMDM, multiple HMDM donor lots were tested by qRT-PCR for the expression level of -arrestin 1 and 2. This revealed that -arrestin 2 had significantly higher (17-fold) expression than -arrestin 1 (Fig. 1A) . This guided the -arrestin isoform of focus for BRET studies of the C5a receptors that best represented the environment within HMDM.
To further understand the relationship between the C5a receptors and -arrestin expression within HMDM, qRT-PCR was also performed to look at the expression levels of the C5a1 and C5a2 receptors. It is widely reported that the C5a receptors are quite often coexpressed in many cell types especially of the myeloid linage 1 , but usually the C5a1 receptor is expressed at a higher level than C5a2 2 . Interestingly, as shown in figure 1B , within HMDM used in this study the C5a2 receptor looks to have slightly higher mRNA expression levels than that of the C5a1 receptor. The qRT-PCR data for the expression of the C5a receptors corresponds with previously published microscopy data on HMDM, which also showed that C5a1 is expressed predominantly on the cell surface whilst C5a2 is predominantly expressed intracellulary 25 .
C5a1 and C5a2 heteromer formation regulates G-CSF release, but not HMGB1 release by HMDM
It has been shown that C5a, but not C5a-des Arg, up-regulates heteromer formation between C5a1-C5a2 at C5a concentrations of > 100 nM, as a mechanism to regulate anti-inflammatory cytokine release 25 . Further support for this observation was demonstrated when differences in G-CSF release induced by C5a and C5a-des Arg at 100 nM from mouse peritoneal elicited macrophages was reported by Bosmann et al. 27 . To further validate the role of C5a upregulated C5a1-C5a2 heteromer formation, G-CSF release from HMDM was quantified using various concentrations of C5a and C5a-des Arg (1, 100 and 200 nM) in the presence of LPS (10 ng/ml). As shown in figure 2A , C5a at 100 and 200 nM induces a significantly elevated release of G-CSF relative to C5a-des Arg, supporting the notion that up-regulation of heteromer formation by C5a modulates anti-inflammatory cytokine release.
It was also hypothesized that C5a1-C5a2 heteromer formation might regulate the release of HMGB1, a known late mediator of acute inflammatory conditions like sepsis, as it has been shown that C5a2 is critical for the release of HMGB1 during acute inflammation 7 .
HMGB1 release was quantified from HMDM with and without LPS (10 ng/ml) at various concentrations of C5a and C5a-des Arg, 24 h after stimulation of the cells. Neither C5a nor C5a-des Arg alone was able to induce a significant increase in the amount of HMGB1 released from HMDM. Whilst in the presence of LPS there is a trend of higher release of HMGB1 the result is not significant and there is no observable difference between C5a and C5a-des Arg (Fig. 3B ). This data suggests that C5a1-C5a2 heteromer formation is not responsible for the modulation of HMGB1 release from macrophages during acute inflammation.
-arrestin 2 recruitment by C5a1 and C5a2 receptors using BRET assay
Initial assays calculating BRET ratio for C5a1 and C5a2 recruitment of -arrestin 2 suggested constitutive formation of a C5a2--arrestin 2 complex, but not for a C5a1--arrestin 2 complex (Fig. 3A, B) . The C5a2--arrestin 2 complex had a BRET ratio of ~0.1 without the presence of ligand (Fig. 3B ) whilst there was no discernable BRET ratio for C5a1--arrestin 2 in the absence of ligand (Fig. 3A) . C5a is able to recruit -arrestin 2 to a similar maximal BRET ratio of 0.25 through both C5a1 and C5a2.
Monitoring ligand induced BRET ratio controls for any constitutive association between the two proteins, as only a ligand-induced change in the BRET ratio is observed.
Interestingly, C5a-des Arg recruited -arrestin 2 to a similar level as C5a through C5a2, but could only recruit -arrestin 2 to ~40% of the level of C5a through C5a1 (Fig. 3C, D) . This result is in agreement to a previous study suggesting C5a-des Arg is a partial agonist for - 3F ). This suggests that even though C5a2 had low surface expression 11, 25, 28 there was a clear preference for C5a and C5a-des Arg to recruit -arrestin 2 through C5a2 over C5a1.
C5a2 modulates C5a1 receptor recruitment of -arrestin 2
To further investigate the ability of C5a and C5a-des Arg to recruit -arrestin 2 through both C5a1 and C5a2, competition BRET assays were performed. This involved co-transfection of an equal amount of either unlabeled C5a1 or C5a2 with the C5a2-Venus/-arrestin 2-Rluc8 or C5a1-Rluc8/-arrestin 2-Venus BRET pairs, respectively. To assist with control of expression, the unlabeled receptor constructs were contained in the same expression plasmid as the labeled receptors, which are under the control of the same promoter. When unlabelled C5a2 was co-transfected with the C5a1-Rluc8/-arrestin 2-Venus BRET constructs there was > 45% reduction in the maximal amount of -arrestin 2 recruited by both ligands (Fig. 4A ).
The C5a2-Venus/-arrestin 2-Rluc8 BRET constructs in the presence of unlabelled C5a1
showed a significantly smaller reduction (< 20%) in the maximal amount of -arrestin 2 recruited by C5a2 (Fig. 4B ).
The effect on the EC 50 values for the C5a1-Rluc8/-arrestin 2-Venus in the presence of the unlabelled C5a2 showed a reduction in potency of ~20 nM and 30 nM for C5a and C5a-des Arg, respectively (Fig. 4C) . However, the C5a2-Venus/-arrestin 2-Rluc8 with unlabelled C5a1 showed the opposite effect with a small increase in potency for C5a and C5a-des Arg of ~ 23 nM and 9 nM, respectively ( Fig. 4D ). This result further suggests that when C5a2 is present on the cell surface with C5a1, there may be a preference to recruit -arrestin 2 through C5a2, which would in turn lead to modulation of C5a1 signaling or alternatively
C5a2 could act as a better ligand-scavenger than C5a1 thereby reducing the effective amount of ligand present.
C5a2 modulates ERK1/2 activation of C5a1 in HMDM
One common signaling pathway for both G-proteins and -arrestins is the ERK1/2 pathway.
It has been previously suggested that C5a2 may modulate ERK1/2 activation by C5a1 in human polymorphonuclear leukocytes 28 . Previous testing of ERK1/2 activation in HMDM has been undertaken, but not at concentrations at or above 100 nM, which is the BRET EC 50
for C5a1-C5a2 heteromer formation 3, 25 . In figure 5A a significant reduction in the amount of ERK1/2 activation by C5a at concentrations at and above 100 nM are depicted, but no change for C5a-des Arg was observed. To eliminate the possibility of technical errors in the dynamic range of the kit, HMDM lysate was diluted and the assay repeated, yielding the same result (data not shown). To exclude any effects due to the use of recombinant C5a versus isolated C5a-des Arg, ERK1/2 assays were performed on HMDM and a C5aR stable cell line using isolated C5a and no difference was observed between isolated and recombinant C5a (data not shown). This suggested that at the concentrations required to increase heteromer formation between C5a1 and C5a2 ERK1/2 activation is reduced, possibly through a C5a2--arrestin mediated mechanism.
C5a and C5a-des Arg possessed similar EC 50 values for ERK1/2 activation of 1.99 ± 0.33 nM and 0.93 ± 0.15 nM, respectively (Fig. 5B) , hence selective ERK1/2 activation is driven by ligand affinity. To further test if C5a2 is responsible for the change in ERK1/2 activation we used a C5a2 Ab (5 µg/ml) to attempt to block C5a2. As is shown in Fig. 5C at a C5a concentration of 10 nM there was a significant increase in ERK1/2 activation, but there was no change in ERK1/2 activation at 100 nM in the presence of the C5a2 Ab. C5a-des Arg had the opposite effect where there was a small, but not statistically significant reduction in the amount of ERK1/2 activation at all concentrations tested was observed (Fig. 5C) . A possible explanation for why there is an effect at the 10 nM, but not the 100 nM, concentration of C5a is that the C5a2 Ab is unable to inhibit heteromer formation between C5a1 and C5a2.
ERK1/2 activation in RBL cells stably expressing C5a1, C5a2 or co-expressing
C5a1/C5a2
To further test the effect of ERK1/2 activation following C5a and C5a-des Arg binding to the C5a receptors, we used RBL cells that stably express C5a1, C5a2 or C5a1/C5a2. RBL cells transfected with empty vectors and the RBL-C5a2 cells showed no ERK1/2 activation in the presence of C5a or C5a-des Arg at concentrations up to 500 nM with a 10 min stimulation time (the same as used for HMDM) (Fig. 6A, B) . The RBL-C5a1 cells showed a robust ERK1/2 activation for both C5a and C5a-des Arg with EC 50 values of 5.2 ± 1 nM and 3 ± 0.5 nM, respectively (Fig. 6C) . The co-transfected RBL-C5a1/C5a2 also had robust ERK1/2 activation for C5a and C5a-des Arg with a ~5 fold reduction in potency with EC 50 values of 23 ± 4 nM and 15 ± 2 nM respectively ( 
DISCUSSION
Having recently shown that increased C5a receptor heteromer formation modulates the release of the anti-inflammatory cytokine IL-10 from HMDM 25 , we wanted to understand the possible signaling mechanism that controlled this process. To further test whether C5a1-C5a2 heteromer formation controls the release of other anti-inflammatory cytokines, the release of G-CSF from HMDM was quantified using both C5a and C5a-des Arg. G-CSF was released from HMDM at significantly higher levels by C5a at concentrations at or above those required for heteromer formation. The increased G-CSF release gives further evidence to the theory that C5a2 acts to modulate C5a1 activity depending on the concentration of C5a present. C5a2 has been shown to be critical for the release of HMGB1 during acute inflammation 7 and it was postulated that C5a1-C5a2 heteromer formation could be a mechanism to control the release of HMGB1. HMGB1 release from HMDM was quantified by ELISA, and there was no observable differences in HMGB1 release initiated by C5a or C5a-des Arg with or without LPS present, suggesting that C5a1-C5a2 heteromer formation was not a regulatory mechanism.
As C5a2 is known to be a non-signaling GPCR 10 , which still binds to -arrestins 11, 12 , we hypothesized that the possible regulation of C5a1 signaling may occur through -arrestins, which have already been shown to have a regulatory role in sepsis-induced inflammation 19 .
Using HMDM as the model system, qRT-PCR analysis was performed to first quantitate the levels of expression of the two main -arrestin isoforms (1 and 2) known to associate with non-visual GPCR 18 . Analysis revealed that -arrestin 2 was expressed at significantly higher levels than -arrestin 1 in HMDM, so -arrestin 2 was chosen as the focus for this study. A BRET based assay was developed to test -arrestin 2 recruitment by C5a and C5a-des Arg through C5a1 and C5a2. Initial data showed that C5a2 had a constitutive interaction with -arrestin 2 that accounted for ~50% of the total BRET signal generated while there was no such evidence for C5a1. When looking at the ability of C5a and C5a-des Arg to recruit -arrestin 2 through C5a1 it was evident that C5a-des Arg was only a partial agonist, being able to generate only ~40% of the BRET signal of C5a. However there was no such difference in -arrestin 2 recruitment by C5a2. The partial agonism observed for C5a-des Arg is in agreement with a previous study 12 and could, in part, explain why C5a-des Arg is unable to up-regulate heteromer formation as was previously shown 25 . Interestingly both C5a and C5a-des Arg had higher potency at C5a2 over C5a1 for the recruitmentof-arrestin 2 with the greatest difference being a three-fold increase in potency for C5a-des Arg. Also C5a showed a difference in the time-course for-arrestin 2 recruitment by C5a1 and C5a2 where C5a-des Arg did not. The time-course for -arrestin 2 recruitment by C5a2 corresponded well with the time-course observed for heteromer formation between C5a1 and C5a2 in a previous study 25 suggesting that C5a2 -arrestin 2 recruitment might control the rate of heteromer formation.
Interestingly, when the BRET experiments were performed in the presence of the corresponding unlabelled receptor (e.g. unlabelled C5a2 co-transfected with C5a1-Rluc8 and -arrestin 2-Venus), there was a significant reduction (> 45%) in the maximal amount of -arrestin 2 able to be recruited through C5a1 for both C5a and C5a-des Arg. Concomitant with the decrease in the maximal signal there was also a reduction in the potency of C5a and C5a-des Arg by 20 nM and 30nM, respectively for -arrestin 2 recruitment through C5a1. While there was an effect on the ability of C5a and C5a-des Arg to recruit -arrestin 2 through C5a2 in the presence of C5a1 it was to a much lower level (< 20%) than seen for C5a1 in the presence of C5a2. Also there was the opposite effect on the potency of C5a and C5a-des Arg with there being an increase in potency for both C5a and C5a-des Arg of 23 nM and 9 nM.
This data supports the evidence for the clear preference of C5a and C5a-des Arg to recruit -arrestin 2 through C5a2. This increased preference to recruit -arrestin 2 through C5a2 may be the mechanism that modulates C5a1 signaling.
One of the intracellular signaling pathways known to interact with both G-proteins and -arrestins is the ERK1/2 pathway 18, 29 . Our group and many others have shown that following C5a binding to C5a1 there is a rapid robust activation of the ERK pathway 3, 28, [30] [31] [32] [33] .
Looking at ERK1/2 activation in HMDM following stimulation with C5a and C5a-des Arg this rapid robust activation of ERK1/2 was observed. However at C5a concentrations (≥ 100 nM) known to up-regulate heteromer formation between C5a1 and C5a2 there was a significant inhibition of ERK1/2 activation that was not observed with C5a-des Arg. This data leads to the suggestion that the formation of the C5a1-C5a2 heteromer might be suppressing the activation of ERK1/2. As was shown, C5a2 forms a constitutive complex with -arrestin 2 similar to that seen for another non-signaling GPCR the chemokine decoy receptor D6 14 although C5a2 doesn't have the constant surface expression observed for D6. A previous study with human neutrophils observed an increase in ERK1/2 activation in the presence of a C5a2 neutralizing antibody 28 . Testing ERK1/2 activation of HMDM in the presence of a C5a2 neutralizing antibody did significantly increase ERK1/2 activation at C5a concentrations below those required to up-regulate heteromer formation, but did not reverse the suppression of ERK1/2 activation observed at C5a concentrations required to up-regulate heteromer formation. We theorized that this was most likely due to the inability of the C5a2
Ab to block the heteromer formation between C5a1 and C5a2. This data gives further evidence that C5a2 is more than just a recycling decoy receptor 11 and has a function in regulating intracellular signaling events. Using RBL cell lines stably expressing C5a1, C5a2
and co-expressing C5a1 and C5a2 we tested the ability of C5a1 and C5a2 to activate ERK1/2.
C5a2 was unable to activate ERK1/2 at any of the concentrations of C5a and C5a-des Arg tested, while robust ERK1/2 activation was observed in the C5a1 and dual C5a1-C5a2 cell lines. There was no observed inhibition of ERK1/2 activation for C5a in the dual transfected cell line. This may be due to the RBL cell line hosting the receptors, as there would presumably be higher expression of the receptors on the transfected cell line compared to HMDM that would effect how the cells respond to activation by ligand.
In conclusion, we propose a possible working model for C5a1-C5a2 heteromer formation by C5a and modulation of ERK1/2 activation via C5a2 mediated -arrestin recruitment. It is likely that the ERK1/2 activation seen at C5a concentrations that up-regulate heteromer formation might be due to a combination of C5a1-induced activation and formation of a C5a1-C5a2 heteromer -arrestin inhibitory complex. In this study, we have shown that
C5a2 forms a constitutive complex with -arrestin 2 and that both C5a and C5a-des Arg have a preference to recruit -arrestin 2 through C5a2. We also have evidence for the ability of the C5a1-C5a2 heteromer to modulate ERK1/2 activation in HMDM. This modulation of ERK1/2 activation may be the mechanism by which C5a receptor heteromers regulate cytokine release. Interestingly it was shown that C5a1-C5a2 heteromer formation might regulate ERK1/2 activation, G-CSF release, but not HMGB1 release from HMDM. It should be noted that this proposed model may only be relevant to human macrophages, as there is an increased understanding within the complement C5a receptor field, that there are signaling and expression differences for the C5a receptors which are both species and cell type specific 1, 2 . A better understanding of the important role -arrestins play in relation to C5a1-C5a2 heteromer formation and the modulation of C5a1 signaling should aid further studies of the role of this complex during acute inflammation.
METHODS
Materials
-arrestin 2-Rluc8 and -arrestin 2-Venus clones were kindly supplied by Associate Prof.
Kevin Pfleger (WAIMR, UWA, Perth, Australia). C5a1-Rluc8 and C5a2-Venus clones were generated previously 25 and kind permission for use of the RLuc8 and Venus constructs was given by Sanjiv Gambhir (Rluc8, Stanford University, CA, USA) and Atsushi Miyawaki 
Cell culture and transfection
HEK293 cells were maintained in DMEM containing 10% FBS, 50 IU per ml penicillin, 50 mg/ml streptomycin (Life technologies) at 37 o C and 5% CO 2 . RBL-2H3 cells stably expressing either empty vector, -C5a1, -C5a2 or -C5a1/C5a2 were cultured in DMEM, 10%
FBS, 50 IU per ml penicillin, 50 mg/ml streptomycin, 800 µg/ml G418 and 1.5 µg/ml puromycin at 37 o C and 5% CO 2 . Transient transfections were performed 24 h after seeding 
BRET assays for the recruitment of -arrestin 2 to C5a receptors
Assay was performed as a ligand-induced BRET experiment similar to previously described 26 . In brief, HEK293 cells were transiently transfected with either C5a1-Rluc8 and -arrestin 
Data and statistical analysis
The Graphpad Prism version 6 software was used for all statistical and graphical analysis (Graphpad Software, La Jolla, CA, USA). Sigmoidal curves were fitted to the dose-response curves using non-linear regression. Data from at least three separate experiments are expressed as mean, and error bars represent SEM. Statistical analysis was performed using either a Student's t-test or by one-way ANOVA with Sidak correction, for multiple comparisons, differences were considered significant if p < 0.05.
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